Thymic stromal lymphopoietin is a key mediator of breast cancer progression

Purevdorj B. Olkhanud, Yrina Rochman, Monica Bodogai, Enkhzol Malchinkhuu, Katarzyna Wejksza, Mai Xu, Ronald E. Gress, Charles Hesdorffer, Warren J. Leonard, Arya Biragyn

Research output: Contribution to journalArticlepeer-review

Abstract

Inflammation is a double-edged sword that can promote or suppress cancer progression. In this study, we report that thymic stromal lymphopoietin (TSLP), an IL-7 - like type 1 inflammatory cytokine that is often associated with the induction of Th2-type allergic responses in the lungs, is also expressed in human and murine cancers. Our studies with murine cancer cells indicate that TSLP plays an essential role in cancer escape, as its inactivation in cancer cells alone was sufficient to almost completely abrogate cancer progression and lung metastasis. The cancer-promoting activity of TSLP primarily required signaling through the TSLP receptor on CD4+ T cells, promoting Th2-skewed immune responses and production of immunosuppressive factors such as IL-10 and IL-13. Expression of TSLP therefore may be a useful prognostic marker, and its targeting could have therapeutic potential.

Original languageEnglish (US)
Pages (from-to)5656-5662
Number of pages7
JournalJournal of Immunology
Volume186
Issue number10
DOIs
StatePublished - May 15 2011

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Thymic stromal lymphopoietin is a key mediator of breast cancer progression'. Together they form a unique fingerprint.

Cite this